Prime Medicine, Inc. Common Stock
$3.12
-$0.02 (-0.64%)
$3.04Day Range$3.17
Key Statistics
Market Cap
$565.90M
Shares Outstanding
181.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 20, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$3.13
Day High
$3.17
Day Low
$3.04
Volume
4.67M
VWAP
$3.12
Prev Close
$3.14
Transactions
--
Acc. Volume
--
About Prime Medicine, Inc. Common Stock
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836146 employees60 FIRST ST., CAMBRIDGE, MA, 02141617-465-0013IPO Oct 20, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001894562
- Composite FIGI
- BBG011RT3R55
- Share Class FIGI
- BBG011RT3R64
- Ticker Root
- PRME
- SIC Code
- 2836
About Prime Medicine, Inc. Common Stock (PRME) Stock
Prime Medicine, Inc. Common Stock (PRME) closed the 2026-09-18 session at $3.12, down 0.64% versus the previous close (-0.02). The stock opened at $3.13 and traded between $3.04 and $3.17 during that session. Session trading volume was 4.7M shares. The volume-weighted average price (VWAP) is $3.12.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Prime Medicine, Inc. Common Stock has a market capitalization of $565.9 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. PRME is listed on the XNAS exchange. The company employs approximately 146 people. Prime Medicine, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2022-10-20.
On this page you can find market PRME stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.